Testing BMS-986525 alone or with pumitamig in small cell lung cancer
Tests BMS-986525, alone or with pumitamig, in adults with small cell lung cancer.
Plain-language title generated from the registry record
Registry title: A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Key facts
- Where
- Madrid, SpainSee the site
- Phase
- Phase 1/2
Where in Spain
- Hospital Universitario 12 de OctubreMadrid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07325136EU 2025-524090-16-00
- Record updated
- 14 September 2026
- Original description
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung CancerRead full original descriptionShow less
A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer
Inclusion: Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC); Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines; In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.
Exclusion: Participants must not have had a prior organ or tissue allograft; Participants must not have an active, known or suspected autoimmune disease; Participants must not have any untreated CNS metastases; Other protocol-defined Inclusion/Exclusion criteria apply.